

ASCO Daily News のトップ記事に
JACCRO GC-07, JACCRO GC-08 が紹介されました。

Meeting Coverage From *ASCO Daily News*



Updated 3-Year Results Confirm the Benefit of Adjuvant S-1 Plus Docetaxel for Stage III Gastric Cancer

Updated data from the GC-07 trial confirmed the recurrence-free survival (RFS) results previously seen with S-1 plus docetaxel and documented a survival advantage as well ([Abstract 159](#)). The 3-year RFS rate reached 67.7% with S-1 plus docetaxel versus 57.4% with S-1 alone, demonstrating clear superiority of the combination.

Abstract 159 Presenter Dr. Kazuhiro Yoshida (pictured)

Meeting Coverage | [Read Now](#)



The Gut Microbiome Offers Clues to Immunotherapy Efficacy in Advanced Gastric Cancer

The DELIVER trial showed that patients with advanced gastric cancer who responded to nivolumab treatment had a more diverse gut microbiome compared with patients who did not respond to the immunotherapy ([Abstract 161](#)).

Abstract 161 Presenter Dr. Yu Sunakawa (pictured)

Meeting Coverage | [Read Now](#)